Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/ASHEDUCATION-2006.1.259PMID 17124070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

  2006cited by this paper
• 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

  2006influential reference
• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

  2006cited by this paper
• 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

  2005cited by this paper
• Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

  2005influential reference
• Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by:.

  2005influential reference
• Role of positron emission tomography in lymphoma.

  2005cited by this paper
• Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

  2005influential reference
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison

  2004cited by this paper
• FDG-PET/CT in re-staging of patients with lymphoma

  2004cited by this paper
• Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.

  2004cited by this paper
• Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

  2004cited by this paper
• Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

  2004influential reference
• Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

  2003cited by this paper
• Utility of FDG-PET scanning in lymphoma by WHO classification.

  2003influential reference
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

  2002cited by this paper
• Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the Method

  2002cited by this paper
• Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL).

  2001cited by this paper
• Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma

  2001cited by this paper
• Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.

  2001cited by this paper
• 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

  2001cited by this paper
• Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.

  2001cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

  2001influential reference
• Whole body positron emission tomography in the treatment of Hodgkin disease

  2001cited by this paper
• 2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

  2001cited by this paper
• Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

  2001cited by this paper
• 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.

  2000cited by this paper
• Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.

  2000cited by this paper
• Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.

  2000cited by this paper
• 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.

  2000influential reference
• The role of positron emission tomography (PET) in the management of lymphoma patients.

  1999cited by this paper
• Med Pediatr Oncol

  1999cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

  1999cited by this paper
• Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.

  1999cited by this paper
• Detection of lymphoma in bone marrow by whole-body positron emission tomography.

  1998influential reference
• 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

  1998cited by this paper
• Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.

  1998influential reference
• Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.

  1998cited by this paper
• Extranodal malignant lymphoma: detection with FDG PET versus CT.

  1998influential reference
• Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome.

  1998influential reference
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

  1997influential reference
• LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.

  1989influential reference
• Residual mass in lymphoma may not be residual disease.

  1988influential reference
• Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.

  1988influential reference
• Restaging laparotomy in the management of the non-Hodgkin lymphomas.

  1982cited by this paper

• The Predictive Value of FDG PET/CT in the Evaluation of Bone Marrow Involvement in Lymphoma Patients

  2022cites this paper
• PET/CT in Hodgkin Lymphoma: An Update.

  2022cites this paper
• Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis

  2021cites this paper
• Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update

  2021cites this paper
• SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

  2021cites this paper
• Computed tomography texture analysis for assessment of chemotherapy response of Hodgkin lymphoma

  2020cites this paper
• Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma

  2020cites this paper
• Treatment of Early Favorable Hodgkin Lymphoma

  2020cites this paper
• Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease

  2020cites this paper
• Production of CAR-T Cells for Clinical Applications

  2020cites this paper
• Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT.

  2019cites this paper
• Benign histiocyte-rich pseudotumor in post treatment mediastinal Hodgkin's lymphoma

  2019cites this paper
• Hodgkin’s lymphoma

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas

  2018cites this paper
• Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution

  2018cites this paper
• Continuing education 18 F-FDG-PET / CT in lymphoma : Two decades of experience

  2017cites this paper
• Extranodal presentation of Hodgkin's lymphoma of the sternum: A case report and review of the literature

  2017cites this paper
• Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients : A Single-institution Experience

  2017cites this paper
• Diagnostic Applications of Nuclear Medicine: Pediatric Cancers

  2016cites this paper
• Splenic histiocyte-rich pseudotumor following chemotherapy for non Hodgkin diffuse large B cell lymphoma.

  2016cites this paper
• Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications

  2015cites this paper
• Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin’s or Non-Hodgkin’s Lymphoma?

  2015cites this paper
• Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults

  2015cites this paper
• Primary and secondary bone lymphomas.

  2015cites this paper
• Current status of FDG-PET/CT in staging of adult lymphoma

  2015cites this paper
• The value of 18F‐FDG PET in pediatric patients with post‐transplant lymphoproliferative disorder at initial diagnosis

  2015cites this paper
• Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.

  2014cites this paper
• Molecular imaging for cancer diagnosis and surgery.

  2014cites this paper
• 18F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder

  2014cites this paper
• HISTIOCYTE RICH PSEUDOTUMOUR OF SPLEEN / SPLENIC LYMPH NODE AFTER CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA – A CASE REPORT

  2014cites this paper
• HODGKINOV LIMFOM: POVEZANOST NALAZA POZITRONSKE EMISIJSKE TOMOGRAFIJE NAKON DVA CIKLUSA KEMOTERAPIJE NA KONAČNI ISHOD LIJEČENJA

  2014cites this paper
• Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

  2013influential citation
• Specificities and complexities of palliative care in haematology

  2013cites this paper
• The role of FDG-PET scanning in assessing lymphoma in 2012.

  2013cites this paper
• Tumoren des lymphatischen Systems

  2013cites this paper
• Epidemiology of malignant digestive neuroendocrine tumours

  2013cites this paper
• ONTINUING EDUCATION PROGRAM : FOCUS . . . he role of FDG-PET scanning in assessing lymphoma n 2012

  2013influential citation
• La place de la TEP au FDG dans l’évaluation des lymphomes en 2012

  2013cites this paper
• Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

  2013cites this paper
• 18F-FDG-PET/CT in lymphoma: two decades of experience.

  2012cites this paper
• Prognostic value of 18F-fluorodeoxyglucose positron emission tomography, computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with pathologically positive neck lymph node

  2012cites this paper
• Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma

  2012influential citation
• 18F-FDG-PET/CT in lymphoma: two decades of experience.

  2012cites this paper
• Treatment of Early Stage Hodgkin Lymphoma

  2012influential citation
• The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma

  2012influential citation
• Successful Treatment in Children with Hodgkin Lymphoma in Greece; A 20-Year Experience in a Single Institution

  2012cites this paper
• Metabolic PET Imaging in Cancer Detection and Therapy Response

  2011cites this paper
• Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?

  2011cites this paper
• False-positive PET/CT for lymphoma recurrence secondary to Langerhans cell histiocytosis.

  2011cites this paper
• Metabolic positron emission tomography imaging in cancer detection and therapy response.

  2011cites this paper
• FDG-PET/CT in lymphoma.

  2011cites this paper
• Der Stellenwert der Positronen-Emissions-Tomographie (18 F- FDG-PET) in Diagnostik und Therapiekontrolle bei Hodgkin- Lymphomen

  2011cites this paper
• Impact of FDG-PET/CT in the management of lymphoma

  2011cites this paper
• 18 F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin ’ s disease : a case report

  2011cites this paper
• Integrin Imaging to Evaluate Treatment Response

  2011cites this paper
• , with Squamous Cell Carcinoma of the Oral Cavity PET and PET / CT of the Neck Lymph Nodes Improves Risk Prediction in Patients

  2011cites this paper
• PET and PET/CT of the Neck Lymph Nodes Improves Risk Prediction in Patients with Squamous Cell Carcinoma of the Oral Cavity

  2011cites this paper
• Classical Hodgkin's Lymphoma

  2011cites this paper
• Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie

  2011cites this paper
• F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin’s disease: a case report

  2011cites this paper
• Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

  2010cites this paper
• Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias

  2010cites this paper
• 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

  2010cites this paper
• Treatment of Hodgkin Lymphoma

  2010influential citation
• Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988–2005: an analysis of 21 734 cases

  2010cites this paper
• Hodgkin's lymphoma therapy: past, present, and future

  2010influential citation
• Histological transformation of follicular lymphoma after treatment: a case evaluated with PET/CT.

  2009cites this paper
• Postchemotherapy histiocyte-rich pseudotumor involving the spleen.

  2009cites this paper
• Hodgkin’s Lymphoma—Patients Assessment and Staging

  2009cites this paper
• La place de la TEP au FDG dans l'évaluation des lymphomes

  2009cites this paper
• Tomografía de positrones con 18F-fluorodesoxiglucosa en la valoración de la respuesta de los linfomas al tratamiento. Revisión sistemática de la literatura y metaanálisis

  2009cites this paper
• [18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis].

  2009cites this paper
• Early and Late Therapy Response Assessment With 18 FFluorodeoxyglucose Positron Emission Tomography in

  2009cites this paper
• Malignant Lymphomas and Lymphadenopathies

  2009cites this paper
• Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.

  2009cites this paper
• Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation?

  2009cites this paper
• Primärdiagnostik, Therapieansprechen und Rezidivdiagnostik maligner Lymphome

  2009cites this paper
• Salvage Therapy for Hodgkin’s Lymphoma

  2009cites this paper
• Bildfusionen: Integriertes PET-CT versus sekundäre Bildfusion

  2009cites this paper
• Imaging of mediastinal tumors.

  2008cites this paper
• Hodgkin's Lymphoma

  2008cites this paper
• Non-Hodgkin lymphoma localization in the pituitary gland: diagnosis by FDG-PET/CT.

  2008cites this paper
• Hypertension Congestive heart failure Peripheral vascular disease Cerebrovascular disease Angina Cardiac arrhythmia Myocardial infarction

  2008cites this paper
• Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy

  2008cites this paper
• Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography

  2008cites this paper
• Pediatric malignancies: synopsis of current imaging techniques.

  2008cites this paper
• Routine bone marrow examination in the initial evaluation of paediatric Hodgkin lymphoma: the Canadian perspective

  2008cites this paper
• Clinical perspectives in lymphoma

  2007cites this paper
• Aktualne wskazania do chemioterapii w wysokich dawkach wspomaganej przeszczepieniem autologicznych komórek układu krwiotwórczego u chorych na nowotwory

  2007cites this paper
• Risk, cure and complications in advanced hodgkin disease.

  2007cites this paper
• Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

  2007influential citation
• Annual Congress of the European Association of Nuclear Medicine

  2007cites this paper
• 18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?

  2007cites this paper
• Review Ar ticle-I

  year unknowncites this paper